CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 73 enrolled
Drug / intervention
Valaciclovir +1 moredrug
Likely dose
Valacyclovir 1g once dailyAI-extracted
Key inclusion· 2
  • ✓HSV-2 seropositive at screening
  • ✓In overall general good health
Key exclusion· 3
  • ✕Active lesions consistent with genital herpes
  • ✕Previous history of symptomatic genital herpes
  • ✕History of recurrent, undiagnosed symptoms consistent with genital herpes

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00116844
NCT00116844Phase 4Completed
CompareCT.gov

Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH

GlaxoSmithKline·interventional·Posted Jul 1, 2005·Updated Feb 12, 2018

In Brief

A Phase 4 clinical trial evaluating Valaciclovir and Placebo for Infections, Herpesviridae. Completed, enrolled 73 participants across 17 sites.

Detailed Summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Herpesviridae
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2005
Enrollment StartMar 29, 2005
Primary CompletionJan 10, 2006
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 21.0 years ago

Interventions

Valaciclovirdrug

Valtrex 1g once daily

Placebodrug

placebo